Thomas Erickson - Amer Renal Independent Director
Director
Mr. Thomas Willard Erickson is an Independent Director of the company. Mr. Erickson also serves as chairman of the executive committee of Luminex Corporationrationration, a developer of biological testing technologies, as a director of syncreon Group Holdings Limited, a transportation logistics services company, and as a director of 3D Systems Corporationrationration, a provider of advanced and comprehensive 3D digital design and fabrication solutions. Mr. Erickson has also held various public company directorships and executive roles, including as chairman of the board and interim president of National Medical Health Card Systems, Inc., a pharmacy benefits manager, interim president and chief executive officer of Luminex Corporation and interim president and chief executive officer of Omega Healthcare Investors, Inc., a healthcare focused real estate investment trust. Mr. Erickson was also chairman of the board of Western Dental Services, Inc., a dental practice management company, and cofounder, president and chief executive officer of CareSelect Group, Inc., a physician practice management company since 2011.
| Age | 68 |
| Tenure | 13 years |
| Professional Marks | MBA |
| Phone | 978 922-3080 |
| Web | www.americanrenal.com |
Thomas Erickson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Thomas Erickson against Amer Renal stock is an integral part of due diligence when investing in Amer Renal. Thomas Erickson insider activity provides valuable insight into whether Amer Renal is net buyers or sellers over its current business cycle. Note, Amer Renal insiders must abide by specific rules, including filing SEC forms every time they buy or sell Amer Renal'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Thomas Erickson over three months ago Acquisition by Thomas Erickson of 568 shares of Bellring Brands subject to Rule 16b-3 |
Amer Renal Management Efficiency
The company has Return on Asset of 4.35 % which means that on every $100 spent on assets, it made $4.35 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 17.51 %, implying that it generated $17.51 on every 100 dollars invested. Amer Renal's management efficiency ratios could be used to measure how well Amer Renal manages its routine affairs as well as how well it operates its assets and liabilities.Amer Renal Assoc has 724.51 M in debt with debt to equity (D/E) ratio of 3.94, meaning that the company heavily relies on borrowing funds for operations. Amer Renal Assoc has a current ratio of 1.03, demonstrating that it is in a questionable position to pay out its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Amer to invest in growth at high rates of return.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Harper | NL Industries | 59 | |
| Cecil Moore | NL Industries | 81 | |
| Margaret McGlynn | Air Products and | 59 | |
| Charles Cogut | Air Products and | 73 | |
| Samuel Smolik | Axalta Coating Systems | 67 | |
| Meredith Mendes | NL Industries | 62 | |
| Matthew Paull | Air Products and | 69 | |
| Yoad Hayash | Supercom | N/A | |
| Dahan Valeria | Supercom | N/A | |
| Thomas Stafford | NL Industries | 90 | |
| Kareem Sethi | Emerson Radio | 41 | |
| Chadwick Deaton | Air Products and | 68 | |
| Robert Mclaughlin | Axalta Coating Systems | 63 | |
| Arie Trabelsi | Supercom | 66 | |
| Edward Monser | Air Products and | 70 | |
| Kin Yuen | Emerson Radio | 64 | |
| Susan Carter | Air Products and | 61 | |
| Steven Chapman | Axalta Coating Systems | 66 | |
| Michael Binney | Emerson Radio | 65 | |
| Deborah Kissire | Axalta Coating Systems | 63 | |
| Rakesh Sachdev | Axalta Coating Systems | 68 | |
Management Performance
| Return On Equity | 17.51 | |||
| Return On Asset | 4.35 |
Amer Renal Assoc Leadership Team
Elected by the shareholders, the Amer Renal's board of directors comprises two types of representatives: Amer Renal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amer. The board's role is to monitor Amer Renal's management team and ensure that shareholders' interests are well served. Amer Renal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amer Renal's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Syed Kamal, President, Co-Founder, Director | ||
| Thomas Erickson, Independent Director | ||
| Jared Hendricks, Independent Director | ||
| John Jureller, Independent Director | ||
| Robert Fish, Independent Director | ||
| Joseph Carlucci, Chairman of the Board, Chief Executive Officer, Co-Founder | ||
| Michael Boxer, Independent Director | ||
| Jeremy Gelber, Independent Director | ||
| Susanne Clark, Independent Director | ||
| Don Williamson, Chief Operating Officer, Executive Vice President | ||
| Christopher Hocevar, Independent Director | ||
| Mark Herbers, Interim Chief Financial Officer, Interim Chief Accounting Officer |
Amer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amer Renal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 17.51 | |||
| Return On Asset | 4.35 | |||
| Profit Margin | (1.11) % | |||
| Operating Margin | 9.73 % | |||
| Current Valuation | 1.26 B | |||
| Shares Outstanding | 34.54 M | |||
| Shares Owned By Insiders | 9.15 % | |||
| Shares Owned By Institutions | 80.77 % | |||
| Number Of Shares Shorted | 608.63 K | |||
| Price To Earning | 144.04 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Amer Stock
If you are still planning to invest in Amer Renal Assoc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Amer Renal's history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |